Chief Executive Officer Craig Wichner said a review of every program, expense and opportunity during his first 100 days confirmed the company's focus on the two programs closest to revenue, sustainable ingredients and rice, while keeping targetedInvestmentin programs such as nutrient use efficiency and …
Chief executive Jeremy Spivey said profitability was well below management's expectations. Adjusted EBITDA was USD 9 million, against USD 21 million a year earlier, and the adjusted EBITDA margin was 4.2%, against 17.5%.
Product revenue was USD 15.7 million, against USD 6.8 million, andResearch and Developmentrevenue was USD 3.5 million, against USD 1.8 million. For the nine months, total revenues were USD 49.4 million, against USD 31.5 million.
Subscription revenue was USD 134.9 million, or 91% of total revenue. Inseyets conversions rose to 75% of the install base at the end of the third quarter, from nearly 65% at the end of the second quarter.
Production at the Blanket Mine reached just over 17,000 ounces in the quarter. Management pointed to two causes. A shortage of compressed air limited mining in the deeper, higher-grade areas, and problems in the metallurgical plant slowed recovery. Four additional compressors were ordered; two …
The company's quarterly filing showsNet Incomeof USD 6.3 million for the quarter, against USD 8.8 million a year earlier. Net income attributable to Cohen & Company Inc. was USD 6.7 million, against USD 4.6 million.
Total revenues were USD 0.2 million for the quarter, against USD 0.1 million in the prior-year period. For the nine months, revenues were USD 0.3 million, against USD 0.4 million. Interest income was USD 0.4 million for the quarter, against USD 0.7 million, and …
Chief Executive Officer James Dentzer said the company continues to make progress in its TakeAim Lymphoma study in primary CNS lymphoma, or PCNSL, a registrational study of emavusertib in combination with ibrutinib in relapsed or refractory patients.
Third-quarter revenue consisted of USD 17.2 million in DefenCath net sales and USD 37.3 million from the rest of the portfolio. The rest of the portfolio comprised USD 31.4 million of product sales and approximately USD 5.9 million of contract revenue and grant income …
The filing shows net income of USD 1,317 thousand, against USD 1,157 thousand in the same quarter a year earlier, with earnings per share of USD 0.12, against USD 0.11.